Analyst Ratings For Eagle Pharmaceuticals (NASDAQ:EGRX)
Today, Royal Bank Of Canada lowered its price target on Eagle Pharmaceuticals (NASDAQ:EGRX) to $81.00 per share.
There are 1 sell rating, 3 buy ratings on the stock.
The current consensus rating on Eagle Pharmaceuticals (NASDAQ:EGRX) is Buy (Score: 2.50) with a consensus target price of $84.00 per share, a potential 57.39% upside.
Some recent analyst ratings include
- On 6/12/2017 Pete A Meyers, CFO, bought 350 with an average share price of $71.49 per share and the total transaction amounting to $25,021.50. View SEC Filing
- On 5/19/2017 David Pernock, Insider, bought 255 with an average share price of $79.69 per share and the total transaction amounting to $20,320.95. View SEC Filing
- On 5/16/2017 David Pernock, Insider, bought 200 with an average share price of $82.24 per share and the total transaction amounting to $16,448.00. View SEC Filing
- On 4/25/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 54,180 with an average share price of $88.38 per share and the total transaction amounting to $4,788,428.40. View SEC Filing
- On 4/3/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 91,332 with an average share price of $83.09 per share and the total transaction amounting to $7,588,775.88. View SEC Filing
- On 3/29/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 106,468 with an average share price of $83.01 per share and the total transaction amounting to $8,837,908.68. View SEC Filing
- On 3/28/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 6,182 with an average share price of $83.02 per share and the total transaction amounting to $513,229.64. View SEC Filing
Recent Trading Activity for Eagle Pharmaceuticals (NASDAQ:EGRX)
Shares of Eagle Pharmaceuticals closed the previous trading session at 53.37 down -16.67 -23.80% with 1,862,111 shares trading hands.